Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Working Capital Changes (2016 - 2024)

Protalix BioTherapeutics (PLX) has 15 years of Other Working Capital Changes data on record, last reported at $1.7 million in Q2 2024.

  • For Q2 2024, Other Working Capital Changes rose 114.05% year-over-year to $1.7 million; the TTM value through Jun 2024 reached $12.7 million, up 171.74%, while the annual FY2023 figure was -$13.2 million, 84.0% down from the prior year.
  • Other Working Capital Changes reached $1.7 million in Q2 2024 per PLX's latest filing, down from $11.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $11.0 million in Q1 2024 and bottomed at -$25.7 million in Q4 2020.
  • Average Other Working Capital Changes over 5 years is -$2.4 million, with a median of -$1.5 million recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: plummeted 7539.47% in 2022, then skyrocketed 895.32% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$25.7 million in 2020, then soared by 99.85% to -$38000.0 in 2021, then crashed by 4150.0% to -$1.6 million in 2022, then tumbled by 630.03% to -$11.8 million in 2023, then soared by 114.05% to $1.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $1.7 million in Q2 2024, $11.0 million in Q1 2024, and -$11.8 million in Q2 2023.